Compare IMCC & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMCC | ASBP |
|---|---|---|
| Founded | 1980 | 2021 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2M | 7.6M |
| IPO Year | N/A | N/A |
| Metric | IMCC | ASBP |
|---|---|---|
| Price | $0.98 | $1.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 58.6K | ★ 1.6M |
| Earning Date | 03-30-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $37,606,703.00 | $1,941.00 |
| Revenue This Year | $47.12 | N/A |
| Revenue Next Year | $12.83 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.92 | N/A |
| 52 Week Low | $0.90 | $1.20 |
| 52 Week High | $7.12 | $632.00 |
| Indicator | IMCC | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 36.68 | 53.17 |
| Support Level | $1.10 | $1.20 |
| Resistance Level | $1.24 | $2.45 |
| Average True Range (ATR) | 0.13 | 0.28 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 40.90 | 10.39 |
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.